Evidence map›Paper›PMID 30987008›Full record

ReviewJournal of clinical medicine2019

Microbiome of the Skin and Gut in Atopic Dermatitis (AD): Understanding the Pathophysiology and Finding Novel Management Strategies.

Jung Eun Kim, Hei Sung Kim

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05719649 (The Efficacy of NTU 101 Lactic Acid Bacteria Powder in the Adjuvant Improvement of Atopic Dermatitis - A Double-blind, Multi-center Randomized, Placebo-controlled Clinical Trial), which is not on this map. Cited by 120 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed, 4 pooled it
22.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05719649 naunknown statusnot on this mapstarted 2023, after this paper: background citation

The Efficacy of NTU 101 Lactic Acid Bacteria Powder in the Adjuvant Improvement of Atopic Dermatitis - A Double-blind, Multi-center Randomized, Placebo-controlled Clinical Trial

TypeinterventionalSponsorSunWay Biotech Co., LTD.Ran2023 to 2023Enrolled72ConditionsAtopic Dermatitis, Atopic Dermatitis EczemaArmsLactic acid bacteria NTU 101, Placebo
3 · Its place in the literature

Who cites it

120 citing papers in PubMed, 4 syntheses or guidelines pooled it, 226 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Therapeutic effects elicited by the probiotic Lacticaseibacillus rhamnosus GG in children with atopic dermatitis. The results of the ProPAD trial.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2022
    Trial
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Residential greenness and atopic dermatitis in Japanese children: Findings from the TMM BirThree cohort study.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026
    Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. The role of the skin microbiome in modulating rosacea.Postepy dermatologii i alergologii · 2026
    Review
  19. Review
  20. Review

60 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Jung Eun KimDepartment of Dermatology, St. Paul's Hospital, The Catholic University of Korea, Seoul 06591, Korea. mdkjeun@naver.com.ORCID 0000-0003-1670-0995
Hei Sung KimDepartment of Dermatology, Incheon St. Mary's Hospital, The Catholic University of Korea, Seoul 06591, Korea. hazelkimhoho@gmail.com.ORCID 0000-0003-0576-0474
St. Paul's Hospital · KRThe Catholic University of Korea Incheon St. Mary's Hospital · KR

Funding

National Research Foundation of Korea 2017R1C1B5016144
6 · The paper itself

Abstract

Atopic dermatitis (AD) is a long-standing inflammatory skin disease that is highly prevalent worldwide. Multiple factors contribute to AD, with genetics as well as the environment affecting disease development. Although AD shows signs of skin barrier defect and immunological deviation, the mechanism underlying AD is not well understood, and AD treatment is often very difficult. There is substantial data that AD patients have a disturbed microbial composition and lack microbial diversity in their skin and gut compared to controls, which contributes to disease onset and atopic march. It is not clear whether microbial change in AD is an outcome of barrier defect or the cause of barrier dysfunction and inflammation. However, a cross-talk between commensals and the immune system is now noticed, and their alteration is believed to affect the maturation of innate and adaptive immunity during early life. The novel concept of modifying skin and gut microbiome by applying moisturizers that contain nonpathogenic biomass or probiotic supplementation during early years may be a preventive and therapeutic option in high risk groups, but currently lacks evidence. This review discusses the nature of the skin and gut flora in AD, possible mechanisms of skin-gut interaction, and the therapeutic implications of microbiome correction in AD.

Indexed as

atopic dermatitisgutmicrobiomemicrobiotaskintherapeutic implications

Identifiers

PMID30987008
PMCPMC6518061
OpenAlexW2930484057

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.